Defunct Company
Total Trials
18
As Lead Sponsor
9
As Collaborator
Total Enrollment
522
NCT03559439
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
Phase: Phase 1
Role: Collaborator
Start: Apr 24, 2018
Completion: Dec 31, 2021
NCT03825718
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Phase: Early Phase 1
Start: Jan 17, 2019
Completion: Dec 1, 2020
NCT03825731
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Completion: Sep 16, 2019
NCT04182581
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Start: Oct 15, 2019
Completion: May 31, 2021
NCT04129099
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Start: Oct 22, 2019
Completion: Jun 30, 2022
NCT04412174
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Start: Jun 30, 2020
Completion: Dec 31, 2022
NCT04412889
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
NCT04626908
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Phase: Phase 1/2
Start: Nov 20, 2020
Completion: Jun 30, 2023
NCT04595162
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Start: Mar 15, 2021
Completion: Dec 15, 2035
NCT05371730
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
Role: Lead Sponsor
Start: May 30, 2022
Completion: Apr 30, 2026
NCT06049342
A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA
Start: Jan 25, 2024
Completion: May 31, 2025
NCT06245018
A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor
Phase: N/A
Start: Feb 1, 2024
Completion: Mar 1, 2030
NCT06441084
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
Start: Jun 30, 2024
Completion: Dec 31, 2031
NCT06741098
A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）
Start: Feb 20, 2025
Completion: Nov 15, 2028
NCT06825169
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease
Start: Mar 1, 2025
Completion: Sep 1, 2028
NCT06941350
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Start: Apr 28, 2025
Completion: May 30, 2027
NCT06978920
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Start: Jun 6, 2025
Completion: Dec 1, 2028
NCT07139431
A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution
Start: Aug 29, 2025
Completion: Apr 21, 2028